Loading...
Loading...
Morgan Stanley upgraded
Edwards Lifesciences CorpEW from Equal-weight to Overweight.
The price target for Edwards Lifesciences has been raised from $135.00 to $168.00.
Edwards Lifesciences shares have gained 62.93 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period.
Edwards Lifesciences' shares fell 0.01 percent to close at $142.44 on Thursday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in